Literature DB >> 11589826

Repetitive intrathecal injections of poliovirus replicons result in gene expression in neurons of the central nervous system without pathogenesis.

C A Jackson1, C Cobbs, J D Peduzzi, M Novak, C D Morrow.   

Abstract

Poliovirus-based vectors (replicons) can be used for gene delivery to motor neurons of the CNS. In the current study, a replicon encoding green fluorescent protein (GFP) was encapsidated into authentic poliovirions, using established procedures. Intrathecal delivery of encapsidated replicons encoding GFP to the CNS of mice transgenic for the human poliovirus receptor did not result in any functional deficits as judged by behavioral testing. Histological analysis of the CNS of mice given a single intrathecal injection of poliovirus replicons encoding GFP revealed no obvious pathogenesis in neurons (or other cell types) within the CNS. The expression of GFP was confined to motor neurons throughout the neuroaxis; a time course of expression of GFP revealed that expression was detectable 24 hr postinoculation and returned to background levels by 120 hr postinoculation. A procedure was devised to allow repetitive inoculation of replicons within the same animal. Behavioral testing of animals that had received 6 to 13 independent inoculations of replicons revealed no functional deficits. Histological analysis of the CNS from animals that had received 6 to 13 sequential inoculations of replicons revealed no obvious abnormalities in neurons or other cell types in the CNS; expression of GFP was demonstrated in neurons 24 to 72 hr after the final inoculation of the replicon. Furthermore, there was no obvious inflammatory response in the CNS after the multiple inoculations. These studies establish the safety and efficacy of replicons for gene delivery to the CNS and are discussed with respect to use of replicons as new therapeutic strategies for spinal cord injuries and/or neurological diseases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11589826     DOI: 10.1089/104303401753153893

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  7 in total

Review 1.  Viral vectors for therapy of neurologic diseases.

Authors:  Sourav R Choudhury; Eloise Hudry; Casey A Maguire; Miguel Sena-Esteves; Xandra O Breakefield; Paola Grandi
Journal:  Neuropharmacology       Date:  2016-02-21       Impact factor: 5.250

2.  Poliovirus Replicon RNA Generation, Transfection, Packaging, and Quantitation of Replication.

Authors:  Ekaterina G Viktorova; Sunil Khattar; Siba Samal; George A Belov
Journal:  Curr Protoc Microbiol       Date:  2018-02-22

Review 3.  Adenoviral virotherapy for malignant brain tumors.

Authors:  Suvobroto Nandi; Maciej S Lesniak
Journal:  Expert Opin Biol Ther       Date:  2009-06       Impact factor: 4.388

4.  Gene therapy trials for the treatment of high-grade gliomas.

Authors:  Adam M Sonabend; Ilya V Ulasov; Maciej S Lesniak
Journal:  Gene Ther Mol Biol       Date:  2007

5.  Cooperative effect of the attenuation determinants derived from poliovirus sabin 1 strain is essential for attenuation of enterovirus 71 in the NOD/SCID mouse infection model.

Authors:  Minetaro Arita; Yasushi Ami; Takaji Wakita; Hiroyuki Shimizu
Journal:  J Virol       Date:  2007-12-05       Impact factor: 5.103

Review 6.  Enterovirus infections of the central nervous system.

Authors:  Ross E Rhoades; Jenna M Tabor-Godwin; Ginger Tsueng; Ralph Feuer
Journal:  Virology       Date:  2011-01-20       Impact factor: 3.616

Review 7.  Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas.

Authors:  Amish C Shah; Dale Benos; G Yancey Gillespie; James M Markert
Journal:  J Neurooncol       Date:  2003-12       Impact factor: 4.506

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.